Ann: Replacement Prospectus-EUG.AX, page-2

Okay i found a bit of info in the sunday times.
Subscribe EUROGOLD ($0.03)
EUG will son re-emerge on the ASX with a new name and code. EUG is acquiring BARDIAG - a swiss public company which has developed a patented, simple blood test for screening and diagnosing early stage lung cancer. The new name is Bardi and ASX code: BD1. Successful development of blood test for early detection of lung cancer would be commercially attractive. Management intends to have a planned further study complete within 24months , which, if successful, could result in the development of an affordable, minimally invasive lung cancer detection test. The capital structure is tight with a capitalisation of $11million. we see the relatively short time-frame for completion of a significant stage in the product development as a positive. Commercialisation strategies include trade sale, joint venture arrangement, or licensing the BARDI lung cancer test to diagnostic companies. We belive this phramacutical reseach company offers the potential for strong returns, after raising up to $3 million in a public offer of 150 million ordinary shares at 2 cents. requotation of shares on the ASX is expected by May 23. State one is managing - see stateone.com.au for details